REGN Regeneron Pharmaceuticals Loading...

From AMGN earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
20:30
Apr 30 ◎
Myrtle Gordon AMGN Q1 FY26 call
Repatha new-to-brand prescriptions surged 44% in Q1, driven by recent positive cardiovascular outcomes data in primary prevention, signaling stronger uptake. — Amgen's momentum is a direct challenge to Regeneron's Praluent, suggesting Amgen is winning in the PCSK9 class based on superior outcomes data.
REGN
MED

About REGN Analyst Coverage

Buzzberg tracks REGN (Regeneron Pharmaceuticals) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Myrtle Gordon.